What regions does NovaPharmaNews cover?

NovaPharmaNews provides pharmaceutical regulatory intelligence for three markets: United States (FDA), European Union (EMA), and Asia-Pacific (NMPA, PMDA, and TGA). Each region has dedicated coverage from regulatory and clinical specialists.

How quickly are new drug approvals reported?

Our editorial team monitors regulatory agency announcements in real time. Breaking news on drug approvals, clinical trial results, and major regulatory decisions are typically published within hours of official announcements.

Who writes the articles on NovaPharmaNews?

Articles are written and reviewed by the NovaPharmaNews editorial team — editors and analysts with pharma, regulatory, and market backgrounds. Author bylines and reviewer attribution appear on every article; see the editorial team directory and editorial policy.

Is NovaPharmaNews content peer-reviewed?

Yes. Stories undergo editorial review by the editorial team before publication, with a named reviewer on YMYL clinical and labeling claims. We cite primary sources including FDA, EMA, ClinicalTrials.gov, patent offices, and company disclosures. Full standards: https://novapharmanews.com/editorial-policy

Pharma intelligence — drugs, trials, patents

4.2K drugs · 800 companies · 335 pipeline programs · 1.6K patents Whitepapers Data sources Editorial policy Authors

YMYL editorial standards Written and reviewed by the NovaPharmaNews editorial team Editorial policy Methodology Full team

Global Pharma Pulse

oncology FDA Jul 20

AACR/ASCO Methods in Clinical 2026 Preview

Why it matters FDA · oncology — Shifts market positioning across oncology with FDA regulatory exposure.

Watch next Monitor follow-on disclosures and consensus revisions tied to key sponsors.

Read full story →

Also driving the week

Insilico–Bora Pharmaceuticals: $2.5B AI AllianceNMPA · Jul 19 JASCAYD (nerandomilast) Wins EU Approval for IPF & PPFEMA · Jul 19

Global market desks

FDA · EMA · NMPA command centers

Three regulatory corridors — top movement in approvals, clinical catalysts, and corporate developments per market.

No recent signal — browse FDA coverage

FDA 2/wk

0 approvals 0 clinical 0 deals

Full FDA desk →

EMA 2/wk

2 approvals 0 clinical 0 deals

Regulatory JASCAYD (nerandomilast) Wins EU Approval for IPF & PPF Company JASCAYD (nerandomilast) Wins EU Approval for IPF & PPF Full EMA desk →

APAC NMPAPMDATGA 2/wk

0 approvals 0 clinical 0 deals

Company Insilico–Bora Pharmaceuticals: $2.5B AI Alliance Full NMPA desk →

Events Next · Jul 22 · Cardinal Health RBC Pipeline Programs & readouts M&A & Licensing Deal & partnership tracker PDUFA & Catalysts Regulatory calendar

Ask about this week's catalysts

AI-assisted answers grounded in NovaPharmaNews intelligence

Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.

Market Signals

All signals →

Regulatory

JASCAYD (nerandomilast) Wins EU Approval for IPF & PPF

nerandomilast (EMA) — Shifts market positioning across Idiopathic Pulmonary Fibrosis with EMA regulatory exposure.

EMA · Jul 19
Clinical

Syndax pipeline update: Revuforj and Niktimvo catalysts to watch

Revuforj (revumenib) is FDA-approved for relapsed or refractory acute leukemia with KMT2A translocation and for relapsed or refractory AML with susceptible NPM1 mutation, both in adult and pediatric patients 1 year and older.

FDA · Jun 8
M&A

Tillomed Laboratories update: pipeline, melphalan and next catalysts

melphalan (FDA) — Tillomed Laboratories is owned by Emcure , a privately held pharmaceutical company positioned as a diversified generics and specialty-pharma business.

FDA · Jun 8
Licensing

Roche's Licensing Deal for Xofluza: Implications and Insights

Roche has signed a significant licensing deal for Xofluza with the Medicines Patent Pool, impacting 129 countries. This article explores the implications for the pharma industry.

EMA · May 21
Manufacturing

PDA Manufacturing APAC: Key Highlights and Takeaways

NMPA · manufacturing — The PDA Pharmaceutical Manufacturing conference in the Asia-Pacific region highlights critical trends reshaping pharmaceutical production, including digital transformation, continuous manufacturing adoption, and supply chain resilience strategies.

NMPA · May 14

This Week's Catalysts

Full calendar →

Jul 22

Cardinal Health RBC

Major congress · Jul 22 · Orlando. Preview and live coverage on the event hub.

Major congress
Jul 24

2026 TPA Conference & Expo

Major congress · Jul 24 · The Woodlands. Preview and live coverage on the event hub.

Major congress
Jul 26

AACR/ASCO Methods in Clinical Cancer Research Workshop 2026

Major congress · Jul 26 · Vail · oncology focus. Preview and live coverage on the event hub.

Major congress
Jul 27

Pharmaceutical Sciences and Innovations in Pharma Industry

Major congress · Jul 27 · Rome. Preview and live coverage on the event hub.

Major congress
Jul 28

The Health Industry Series – ASEAN (tHIS ASEAN)

Major congress · Jul 28 · Kuala Lumpur. Preview and live coverage on the event hub.

Major congress
Aug 17

Annual NPPA Conference 2026

Major congress · Aug 17 · Las Vegas. Preview and live coverage on the event hub.

Major congress

Who to Watch

Companies to watch

Pfizer Pipeline indexed

Why nowPfizer — active Hypertension, Breast Neoplasms portfolio with Pipeline indexed tracked across pipeline, patents, and deals.

Janssen Research & Pipeline indexed

Why nowJanssen Research & — active Ventilator-Associated Pneumonia, Carcinoma, Squamous Cell portfolio with Pipeline indexed tracked across pipeline, patents, and deals.

HOFFMANN-LA ROCHE 4 programs

Why nowHOFFMANN-LA ROCHE — active Breast Cancer, Multiple Sclerosis (MS) portfolio with 4 programs tracked across pipeline, patents, and deals.

Novartis Pipeline indexed

Why nowNovartis remibrutinib wins Phase 3 in CSU: what it means

Company graph →

Drugs to watch

Keytruda (pembrolizumab) approved

Why nowKeytruda (pembrolizumab) — approved · Antineoplastic and immunomodulating agents (L01). Patents, biosimilar entry, and linked trials tracked on the profile.

Ozempic / Wegovy (semaglutide) approved

Why nowOzempic / Wegovy (semaglutide) — approved · Alimentary tract and metabolism (A10). Patents, biosimilar entry, and linked trials tracked on the profile.

Mounjaro (tirzepatide) approved

Why nowMounjaro (tirzepatide) — approved · Alimentary tract and metabolism (A10). Patents, biosimilar entry, and linked trials tracked on the profile.

Opdivo (nivolumab) approved

Why nowOpdivo (nivolumab) — approved · Antineoplastic and immunomodulating agents (L01). Patents, biosimilar entry, and linked trials tracked on the profile.

Drug graph →

Editorial Intelligence

All analysis →

oncology

AACR/ASCO Methods in Clinical 2026 Preview

FDA · oncology — Shifts market positioning across oncology with FDA regulatory exposure.

FDA · Jul 20

NMPA

Insilico–Bora Pharmaceuticals: $2.5B AI Alliance

Insilico Medicine (NMPA) — Shifts market positioning across pharma with NMPA regulatory exposure.

NMPA · Jul 19